Human clinical trials |
Study participants n > 100 |
Measurement of the participants' DPYD‐genotype |
Treatment with systemic treatment with 5‐FU, Capcitabin or Tegafur (teysuno), |
Data regarding adverse events after treatment |
Cancer treatment |
Human clinical trials |
Study participants n > 100 |
Measurement of the participants' DPYD‐genotype |
Treatment with systemic treatment with 5‐FU, Capcitabin or Tegafur (teysuno), |
Data regarding adverse events after treatment |
Cancer treatment |